Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Vascular Diseases & Diabetic Retinopathy I

10:30 - 12:00 | 05 September | Room: Speakers' Corner.

Back to Previous

10:30Analysis of retinal layer thickness and choroidal thickness in diabetic macular oedema treated with ranibizumab or aflibercept
S. Oruc Dundar Turkey
10:35Anterograde optic neuropathy and associated retrograde degeneration after branch retinal vein occlusion
S. Yu Switzerland
10:40Automated detection and quantification of spectral domain optical coherence tomography hyper-reflective foci in eyes with retinal vein occlusion
C. Mitsch Austria
10:45Changes in systemic oxidative stress in response to intravitreal anti-vegf therapy for patients with retinal vein occlusions
D. Hwang Taiwan
10:50Educational tool kit for diabetic eye disease
O. Galvin Ireland
10:55Evaluating the impact of a new national diabetic retinopathy screening programme on patient knowledge of HbA1c following referral to a regional treatment centre
J. Hui Min Singapore
11:00Increased risk of cancer in patients with retinal vein occlusion: a 12-year nationwide cohort study
M. Kim South Korea
11:05Intravitreal bevacizumab responsiveness after dexamethasone implants in diabetic macular edema patients previously refractory to intravitreal bevacizumab
J. Kwon South Korea
11:10Long term effects of pan-retinal photocoagulation in diabetic retinopathy in choroid, retina and in visual field
I. Pacheco Soares Carneiro Portugal
11:20Real-time data on the clinical outcomes of fluocinolone acetonide (Iluvien) implant use in chronic diabetic macular oedema in pseudophakic patients
M. Fenech UK
11:35Spectral-domain optical coherence tomography reveals subtle vascular changes in patients with Waldenström´s macroglobulinemia
A. Willerslev Denmark
11:40The comparison of reduced fluence photodynamic therapy with modified or conventional irradiation area for central serous chorioretinopathy
M. Hayashida Japan
11:45The impact of prior therapies on visual acuity outcomes achieved with the 0.19 mg fluocinolone acetonide implant – insights from the UK Medisoft audit study
C. Bailey UK
11:50The quantification of retinal inflammatory biomarkers after treatment of naïve diabetic macular edema.
S. Bini Italy
Back to Previous

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved